Envarsus xr and Peripheral swelling - a phase IV clinical study of FDA data

Summary:

Peripheral swelling is reported as a side effect among people who take Envarsus xr (tacrolimus), especially for people who are female, 60+ old, also take Vitamin D3, and have Cytomegalovirus infection.

The phase IV clinical study analyzes which people have Peripheral swelling when taking Envarsus xr. It is created by eHealthMe based on reports of 3,807 people who have side effects when taking Envarsus xr from the FDA, and is updated regularly.

What is Envarsus xr?

Envarsus xr has active ingredients of tacrolimus. eHealthMe is studying from 3,819 Envarsus xr users. Check the latest studies of Envarsus xr.

What is Peripheral swelling?

Peripheral swelling is found to be associated with 2,182 drugs and 1,743 conditions by eHealthMe. Check the latest studies of Peripheral swelling.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

3,807 people reported to have side effects when taking Envarsus xr.
Among them, 26 people (0.68%) have Peripheral swelling.

Could Envarsus xr cause Peripheral swelling?

Among these 26 people:

What is the gender of people who have Peripheral swelling when taking Envarsus xr? *

female: 65.38 %
male: 34.62 %

What is the age of people who have Peripheral swelling when taking Envarsus xr? *

What are other drugs people take besides Envarsus xr? *

What are other side effects people have besides Peripheral swelling? *

Blood Creatinine Abnormal: 4 people, 15.38%
Haematoma (collection of blood outside the blood vessels): 3 people, 11.54%
Inflammation: 3 people, 11.54%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 3 people, 11.54%
Anaemia (lack of blood): 3 people, 11.54%
Arrhythmias (irregular heartbeat): 3 people, 11.54%
Cardiac Arrest: 3 people, 11.54%
Cardiac Failure: 3 people, 11.54%
Cardiogenic Shock (inadequate circulation of blood): 3 people, 11.54%
Drug Ineffective: 3 people, 11.54%

What are the existing conditions these people have? *

Immune Tolerance Induction: 3 people, 11.54%
Cytomegalovirus Infection: 3 people, 11.54%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 7.69%
Sedation: 2 people, 7.69%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 7.69%
Pain: 1 person, 3.85%
Hypersensitivity: 1 person, 3.85%
Hyperkalemia (damage to or disease of the kidney): 1 person, 3.85%
Fever: 1 person, 3.85%
Constipation: 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Envarsus xr and have Peripheral swelling?

- Check whether Peripheral swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Envarsus xr:

Envarsus xr (3,819 reports)

Browse all side effects of Envarsus xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral swelling:

Peripheral swelling (2,182 drugs)

Browse all the conditions that are associated with Peripheral swelling:

Peripheral swelling (1,743 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Envarsus xr) and Envarsus xr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.